Comparison on clinical efficacy and serum levels of IL-35 and NF-kappa B of rosuvastatin and atorvastatin in patients with coronary heart disease
10.7501/j.issn.1674-6376.2017.08.022
- VernacularTitle:瑞舒伐他汀和阿托伐他汀对冠心病患者的临床疗效及对血清中IL-35、NF-κB水平影响的比较
- Author:
Rui LIU
1
;
fen Yan LIU
Author Information
1. 延安市人民医院
- Keywords:
rosuvastatin;
atorvastatin;
coronary heart disease;
inflammation reaction
- From:
Drug Evaluation Research
2017;40(8):1141-1144
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy and serum levels of IL-35 and NF-κB of rosuvastatin and atorvastatin in patients with coronary heart disease.Methods i00 patients with coronary heart disease were selected,they were divided into two groups according to different statins.The control group (49 cases) was given atorvastatin calcium tablets.The observation group (51 cases) was given rosuvastatin calcium tablets.The effect of different statins in treatment of coronary heart disease was evaluated by lipid levels,IL-35,NF-κB level before and after treatment,adverse reaction during treatment.Results Before treatment,The TG,TC,LDL-C,HDL-C levels of two groups had no significant difference.After treatment,the TG,TC,LDL-C levels of two groups were decreased,and the LDL-C level in the observation group was lower than that of the control group (P ＜ 0.05).The TG,TC level had no significant differences between two groups.After treatment,the HDL-C levels were increased in two groups.There were no significant differences between groups.Before treatment,there were no statistical significance on serum IL-35,NF-κB level.After treatment,the IL-35 level was increased and NF-κB was decreased in two groups (P ＜ 0.05).And the IL-35 level was higher than that of the control group,the NF-κB level was lower than that the control group (P ＜ 0.05).During treatment,there was no statistical significance on adverse reaction between two groups.Conclusion Rosuvastatin and Atorvastatin have good lipid-lowering effect on coronary heart disease.Rosuvastatin can reduce the LDL-C obviously.These drugs can control the inflammation reaction,with less adverse reaction.It is the ideal lipid-lowering drug in clinical treatment of coronary heart disease.
